AzTrials
AzTrials

Ischemia Reperfusion InjuryPAFFIRDNCT06523920

Protecting Autologous Free Flaps From Ischemia/Reperfusion Damage With Cold Storage.

A study testing University of Wisconsin solution + cold storage and Unperfused free flap under warm ischemia in people with Ischemia Reperfusion Injury, run by University of Cagliari.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Reconstructive microsurgery allows autologous transplantation of flaps. The procedure causes temporary ischemia. The absence of perfusion and the post-anastomosis reperfusion causes ischemia/reperfusion (I/R) damage and an increased percentage of flap complications associated with the longer duration of the ischemia… Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Ischemia Reperfusion Injury
What is being tested?
University of Wisconsin solution + cold storage and Unperfused free flap under warm ischemia
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
90 participants
Where
No sites listed yet
Study dates
1 Aug 2024to 30 Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Post-oncological mandible reconstruction through fibula free flap,
  • Post-oncological soft tissue reconstruction through ALT (Anterior Lateral Thigh) free flap in head and neck region
  • Post-oncological breast reconstruction through DIEP (Deep Inferior Epigastric Perforator) and PAP (Profunda femoris Artery Perforator) free flaps.

Who cannot join

  • Malnutrition
  • Malabsorption
  • Vasculitis
  • Pathologies of the connective tissue

Trial locations and contacts

No sites are listed yet.

Filippo Boriani, Prof contact

+393297604660

borianifilippo@gmail.com

About this study

Official title: Protecting Autologous Free Flaps From Ischemia/Reperfusion Damage With Cold Storage: a Randomized Controlled Trial

Reconstructive microsurgery allows autologous transplantation of flaps. The procedure causes temporary ischemia. The absence of perfusion and the post-anastomosis reperfusion causes ischemia/reperfusion (I/R) damage and an increased percentage of flap complications associated with the longer duration of the ischemia time. In reconstructive surgery the utilization of preservation solution is very limited. The research hypothesis is that cold storage of free flaps might offer benefits. The present study is a RCT to evaluate the feasibility and safety of a cold preservation (using the UW solution) of the free flaps from I/R damage in oncological microsurgical reconstructions. Blood perfusion will be intraoperatively evaluated through indocyanine green and SPY-DHI.

Moreover, patients' outcomes will be evaluated postoperatively through clinical and radiological examinations, particularly focusing on somatosensory recovery and dental rehabilitation after mandibular reconstruction.

Read the detailed description

Status of the art Reconstructive microsurgery, via microvascular anastomosis of 0.5 mm to 3 mm vessel diameter, needing an operating microscope, allows autologous transplantation of tissue blocks (flaps) from a donor site to a distant recipient site. The procedure involves temporary ischemia. The absence of perfusion and the post-anastomosis reperfusion causes ischemia/reperfusion (I/R) damage. There is clinical evidence supporting an increased percentage of flap complications associated with the longer duration of the ischemia time. At present, although there are several preservation solutions, for solid organ preservation the University of Wisconsin (UW) solution is still considered the gold standard. Cold storage is also used in autologous liver bench surgery, but not for microvascular reconstruction. Unfortunately, this application of ischemia preservation did not occur in microvascular reconstruction because flaps were considered less prone to damage, having a less functional role, pertaining simply to "filling" or "reshaping". However, this is not the whole truth, if we consider for example the fibula flap, containing an abundance of muscle, which is a vulnerable tissue, and above all the fibula free flap requires a great deal of bone healing, which is necessary for the following dental implants. Moreover, the quality preservation of the original tissues is of paramount clinical relevance if we think about the importance of a soft breast, of a pliable facial reconstruction and, above all, of a functional recovery in a replanted finger, where fibrotic degeneration may cause a functional disaster in terms of range of motion and sensation recovery. To our knowledge, in reconstructive surgery, except for reconstructive transplantation (Vascularized Composite Allotransplantations, VCA), the utilization of preservation solution is very limited.

However, in reconstructive microsurgery and hand/finger replantation, the warm ischemia time can be significantly longer due to flap preparation and difficult implanting within the recipient site, or due to intraoperative technical problems, and some flaps include tissues more vulnerable to warm ischemia time; consequently, it could be useful to use the same procedures employed in VCA to limit I/R injury. A comparative evaluation of the effects of cold preservation of auto-transplanted tissues versus the traditional treatment in which no preservation is performed is non-existing in the medical literature. This lack of scientific knowledge warrants the organization of studies investigating these unexplored aspects of microvascular reconstructive surgical science.

Aims The research hypothesis determining the objectives of this project is that cold static storage of autologous free flaps might offer benefits in terms of flap survival and better preservation of all tissues within the flaps, reducing the incidence of complications, flap shrinkage and the amount of fibrosis induced by I/R damage. Indeed, despite a flow-through and patent microvascular anastomoses, microcirculation and perfusion of the flap can be impaired due to endothelial damage, possibly induced by the I/R traumatic experience that can lead to irreversible fibrosis ending in partial necrosis of the flap and could also explain the significant complication rate (36.1% in head and neck surgery and 35% in breast surgery according to recent studies) in terms of partial flap loss or other early and late complications (Clavien-Dindo grade III), which are more frequent than total flap loss, reported around 2-3% of free tissue transfers in the breast and head and neck regions (2% in breast microsurgical reconstruction and 1-3% in head and neck reconstructions based on published reports). The University of Wisconsin (UW) solution is still considered the gold standard among the preservation solutions in solid organ transplantation as well as in VCA. The UW solution was developed by the surgeon Folkert Belzer and the basic scientist James Southard at the University of Wisconsin in the 1980s and was introduced for clinical use in the United States in 1987. UW solution is characterized by a buffer system (phosphate buffer), with high potassium and low sodium as electrolytes, which mimics the intracellular milieu; in addition, it contains raffinose and lactobionic acid, as osmotic membrane-impermeable agents, molecules that have a large molecular weight (594 and 358 Da) and counteract the transmembranous water shift to prevent cellular edema.

Hydroxyethyl starch was also added as an oncotic substance to prevent expansion of the extracellular space. However, hydroxyethyl starch confers the relatively high viscosity (5.70 cp) to UW solution, which is approximately four times higher than water. Overall the electrolyte composition and the membrane-impermeable macromolecules in UW solution maintain the ionic and osmotic balance during hypothermia. Allopurinol was added as an inhibitor of xanthine oxidase, which blocks the generation of reactive oxygen species (ROS) via the hypoxanthinexanthine- uric acid pathway. The antioxidant glutathione was added to neutralize ROS that are generated during reoxygenation at the time of reperfusion. UW solution also includes adenosine, which serves as a substrate for the resynthesis of ATP on reperfusion. UW solution also omitted Ca2+ because of the extremely low physiological intracellular Ca2+ concentration and the known negative effects of elevated intracellular Ca2+ concentration for cell survival. At present, in literature cold storage for autologous microvascular free tissue transfers has not been reported. Therefore, this project aims to reduce the risks of total and partial free flap failure or fibrotic degeneration and consequent early and late complications, using perfusion of the flaps and their cold storage in UW solution to reduce the I/R damage. Indeed, although the total ischemia time is significantly shorter in autologous free flaps compared to those reported in solid organ transplantation, the longer warm ischemia times sometimes reported in reconstructive surgery should be avoided or somehow neutralized. Moreover, in hand and finger replantation, where surgery is not elective but emergency-based, ischemia times may often be significantly longer.

Sudden circulation interruption alters cellular oxygen and nutrient supply, inducing mitochondrial damage and affecting the metabolic function of the tissues. Reperfusion suddenly restores oxygen and nutrient supply and, following the ischemic time, represents a challenge for the flap tissues that may become particularly sensitive to ROS production. ROS trigger free radical attack to cellular membrane polyunsaturated fatty acids (PUFA) and induce lipid peroxidation, with the formation of unstable fatty acid hydro(pero)xides, eicosanoids, and non-enzymatic (free radical-induced) isoprostanes capable of further propagating free radical reactions thereby extending the damage. I/R damage has a described role in hampering flap integration within the recipient site, its normal and smooth healing with the highst possible degree of similarity to the native preoperative donor tissue. I/R damage determines fibrotic reactions and consequent damage to the neurosensory function due to interference of the scar tissue with the nerve network. In case of mandibular reconstruction, I/R damage is supposed to worsen the quality of bone stock in the reconstructied neomandibula, thereby reducing the possibility of osteointegrated dental implants. Purpose of the study is to evaluate the effect of cold preservation on reconstructive flaps for the breast and head \& neck areas, in terms of multiple clinical and radiological endpoints, with a focus on intraoperative evaluation of perfusion, and postoperative neurosensory recovery and quality of the bone in fibula-based mandibular reconstruction, in view of dental implant osteo-integration.

Project The present study is a RCT to evaluate the efficacy of cold preservation of free flaps from I/R damage in post-oncological microsurgical reconstructions. The study design will conform to the CONSORT guidelines for RCTs. The project has been approved by the local IRB. An anonymous database (only patient initials) will be created to record all the included patients' data and it will not be available to the blinded outcomes assessors. The recorded data will be ischemia time (the time between vessel division and reperfusion at the end of microvascular anastomoses), weight of the flap and duration of surgery, patients' demographics, BMI, smoking and comorbidities. Two randomization lists (breast and head \& neck) will be created through a randomization list generator, available online (random.org), with a 5 block assignment to Group A (flap preserved in UW solution and cold storage during the ischemia time) and Group B (flap without perfusion and cold storage). The randomization will be kept blinded to the outcome assessors and the radiologists. Once harvested and detached from their donor sites, the flaps of Group A will be flushed with 200 ml UW solution at 4°C into the flap artery within 2 minutes after vessel division.

Following the intra-flap injection of the first 150 ml, the last 50 ml of solution will be used to externally irrigate the outer flap, which will be stored at 4°C during the bench surgery and the anastomoses. Before its reperfusion, the flap will be flushed again through its artery with 0.9% saline solution. The flaps of Group B will be stored at room temperature during the bench surgery and the anastomosis time.

Being tested
University of Wisconsin solution + cold storage, Unperfused free flap under warm ischemia
Keywords
free flap, microsurgery, cold ischemia
Medical subject headings
Reperfusion Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • University of Wisconsin solution + cold storageDevice

    Preservation of the free flap with UW solution and cold storage during ischemia time

  • Unperfused free flap under warm ischemiaOther

    Traditional processing of the free flap: no perfusion of the flap and warm ischemia (room temperature conservation during ischemia time

Study groups in NCT06523920
Study groupRoleWhat they receive
UWsolutionExperimentalFlap preserved in UW solution and cold storage during the ischemia time
Receives: Device: University of Wisconsin solution + cold storage
No perfusionSham comparatorFlap without perfusion and cold storage
Receives: Other: Unperfused free flap under warm ischemia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of total flap loss

    Frequency of flaps that suffer from complete loss and are removed evaluated through fluorescence after the injection of indocyanine green by means of SPY PHI (Portable Handheld Imager) by Stryker (Kalamazoo, USA),

    Measured: 1 month

  2. Rate of partial flap loss

    Frequency of flaps that suffer from partial loss and are debrided

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jul 2024
  2. Study start1 Aug 2024 (estimated)
  3. Primary completion30 Jun 2025 (estimated)
  4. Study completion30 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06523920
Sponsor's protocol ID
MUR: P2022EEZ8R
Acronym
PAFFIRD
Status last verified
Jul 2024
First submitted
29 Jun 2024
Last updated
26 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared with other researchers, they will be kept confidential as per legal requirements

Publications

  • Dubay D, Gallinger S, Hawryluck L, Swallow C, McCluskey S, McGilvray I. In situ hypothermic liver preservation during radical liver resection with major vascular reconstruction. Br J Surg. 2009 Dec;96(12):1429-36. doi: 10.1002/bjs.6740.

    PubMed 19918862
  • Saeb-Parsy K, Martin JL, Summers DM, Watson CJE, Krieg T, Murphy MP. Mitochondria as Therapeutic Targets in Transplantation. Trends Mol Med. 2021 Feb;27(2):185-198. doi: 10.1016/j.molmed.2020.08.001. Epub 2020 Sep 17.

    PubMed 32952044
  • Hegge JO, Southard JH, Haworth RA. Preservation of metabolic reserves and function after storage of myocytes in hypothermic UW solution. Am J Physiol Cell Physiol. 2001 Sep;281(3):C758-72. doi: 10.1152/ajpcell.2001.281.3.C758.

    PubMed 11502553
  • Coriddi M, Myers P, Mehrara B, Nelson J, Cordeiro PG, Disa J, Matros E, Dayan J, Allen R, McCarthy C. Management of postoperative microvascular compromise and ischemia reperfusion injury in breast reconstruction using autologous tissue transfer: Retrospective review of 2103 flaps. Microsurgery. 2022 Feb;42(2):109-116. doi: 10.1002/micr.30845. Epub 2021 Dec 2.

    PubMed 34854501
  • Suh JD, Sercarz JA, Abemayor E, Calcaterra TC, Rawnsley JD, Alam D, Blackwell KE. Analysis of outcome and complications in 400 cases of microvascular head and neck reconstruction. Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):962-6. doi: 10.1001/archotol.130.8.962.

    PubMed 15313867
  • Peeters WJ, Nanhekhan L, Van Ongeval C, Fabre G, Vandevoort M. Fat necrosis in deep inferior epigastric perforator flaps: an ultrasound-based review of 202 cases. Plast Reconstr Surg. 2009 Dec;124(6):1754-1758. doi: 10.1097/PRS.0b013e3181bf7e03.

    PubMed 19952630
  • Heidekrueger PI, Moellhoff N, Horch RE, Lohmeyer JA, Marx M, Heitmann C, Fansa H, Geenen M, Gabka CJ, Handstein S, Prantl L, von Fritschen U. Overall Complication Rates of DIEP Flap Breast Reconstructions in Germany-A Multi-Center Analysis Based on the DGPRAC Prospective National Online Registry for Microsurgical Breast Reconstructions. J Clin Med. 2021 Mar 2;10(5):1016. doi: 10.3390/jcm10051016.

    PubMed 33801419
  • Nagel TH, Hayden RE. Mayo Clinic Experience with Unfavorable Results After Free Tissue Transfer to Head and Neck. Clin Plast Surg. 2016 Oct;43(4):669-82. doi: 10.1016/j.cps.2016.05.005. Epub 2016 Jun 22.

    PubMed 27601391
  • Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation. 1988 Apr;45(4):673-6. doi: 10.1097/00007890-198804000-00001. No abstract available.

    PubMed 3282347
  • Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res. 1997 Mar;36(1):1-21. doi: 10.1016/s0163-7827(97)00001-5.

    PubMed 9373618
  • Banni S, Montisci R, Sanfilippo R, Finco G, Sanna D, Giordano E, Murru E, Cordeddu L, Carta G, Banni D, Marchi A. Physiological response to lipid peroxidation in ischemia and reperfusion during carotid endarterectomy. Lipids Health Dis. 2010 Apr 21;9:41. doi: 10.1186/1476-511X-9-41.

    PubMed 20409338
  • Iannone A, Petroni A, Murru E, Cordeddu L, Carta G, Melis MP, Bergamini S, Casa LD, Cappiello L, Carissimi R, O'Shea M, Bell D, De Santis E, Banni S. Impairment of 8-iso-PGF(2ALPHA) isoprostane metabolism by dietary conjugated linoleic acid (CLA). Prostaglandins Leukot Essent Fatty Acids. 2009 May-Jun;80(5-6):279-87. doi: 10.1016/j.plefa.2009.02.008. Epub 2009 Apr 28.

    PubMed 19403295
  • Ebner JJ, Mehra T, Gander T, Schumann P, Essig H, Zweifel D, Rucker M, Slankamenac K, Lanzer M. Novel application of the Clavien-Dindo classification system and the comprehensive complications index(R) in microvascular free tissue transfer to the head and neck. Oral Oncol. 2019 Jul;94:21-25. doi: 10.1016/j.oraloncology.2019.05.005. Epub 2019 May 9. No abstract available.

    PubMed 31178208
  • Katsuragi Y, Kayano S, Akazawa S, Nagamatsu S, Koizumi T, Matsui T, Onitsuka T, Yurikusa T, Huang WC, Nakagawa M. Mandible reconstruction using the calcium-sulphate three-dimensional model and rubber stick: a new method, 'mould technique', for more accurate, efficient and simplified fabrication. J Plast Reconstr Aesthet Surg. 2011 May;64(5):614-22. doi: 10.1016/j.bjps.2010.08.010. Epub 2010 Sep 29.

    PubMed 20884306
  • Zhang L, Liu Z, Li B, Yu H, Shen SG, Wang X. Evaluation of computer-assisted mandibular reconstruction with vascularized fibular flap compared to conventional surgery. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Feb;121(2):139-48. doi: 10.1016/j.oooo.2015.10.005. Epub 2015 Oct 23.

    PubMed 26792754

Questions about this trial

What is this clinical trial studying?

A study testing University of Wisconsin solution + cold storage and Unperfused free flap under warm ischemia in people with Ischemia Reperfusion Injury, run by University of Cagliari.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Filippo Boriani, Prof (+393297604660, borianifilippo@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of total flap loss (time frame: 1 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06523920, which also lists 25 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in